HengRui spreads its SERD
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
Two more companies try to outdo Rybrevant
After Genmab’s exit two more ADCs enter human trials.
Huabo goes pivotal with bispecific VEGF trap
The company takes a PD-L1 x VEGF asset into phase 3.
Moderna investors prepare for a phase 3 reveal
Intismeran autogene’s Interpath-001 trial reads out this year.
Two more in vivo Cars head for the clinic
New first-in-human study initiations feature yet more in vivo Car assets.
Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
Innovent gives another cytokine a shot
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
ArriVent moves to take on Rybrevant
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
